Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis

LOS ALTOS, Calif., Dec. 18, 2023 -- Unicycive Therapeutics, Inc. , a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced the enrollment of...

Related Keywords

United States ,Shalabh Gupta ,Nasdaq ,Exchange Commission ,Linkedin ,Globenewswire Inc ,Unicycive Therapeutics Inc ,Company Or Unicycive ,Reason Research ,Youtube ,Shire International Licensing ,Oxylanthanum Carbonate ,Chief Executive Officer ,New Drug Application ,End Stage Renal Disease ,Private Securities Litigation Reform Act ,Risk Factor ,Annual Report ,Markets ,